Uprosertib

N/A

Report date: 2025/05/28 16:57:02
NME

Base Information

Drug NameUprosertib
Drug Alias NameUprosertibum优普色替乌洛舍替GSK-795GSK-2141795 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase AKT1 inhibitorsSerine/threonine-protein kinase AKT2 inhibitorsSerine/threonine-protein kinase AKT3 inhibitors
TargetsSerine/threonine-protein kinase AKT2Serine/threonine-protein kinase AKT3Serine/threonine-protein kinase AKT1
Therapy Area/IndicationsUveal melanomaSkin MelanomaSolid tumours +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline PlcNovartis Pharma AgNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcNovartis Pharma AgNational Cancer Institute +[4] 
Inactive CompaniesDana-Farber Cancer Institute
Active IndicationsUveal melanomaSkin MelanomaSolid tumours +[6] 
Inactive IndicationsUterine Cervical NeoplasmsEndometrial NeoplasmsUterine Neoplasms +[9] 

Other Information

ATC CodeN/A
Related LinksKEGG